Showing results (171-180 of 182) with videos related to

Sort By:
Pageof 19
Tumour Virus Research|April 23, 2022
Oral human papillomavirus prevalence, persistence, and risk-factors in HIV-positive and HIV-negative adultsJames Riddell, Andrew F Brouwer, Heather M Walline, et al.
Blood|March 12, 2014
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemiaJennifer R Brown, John C Byrd, Steven E Coutre, et al.
Annals of Surgery Open : Perspectives of Surgical History, Education, and Clinical Approaches|January 2, 2023
Impact of the COVID-19 Pandemic on Liver Cancer Staging at a Multidisciplinary Liver Cancer ClinicDaniel Li, Angela Y Jia, Jane Zorzi, et al.
The Journal of Clinical Investigation|April 26, 2016
CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patientsCameron J Turtle, Laïla-Aïcha Hanafi, Carolina Berger, et al.
Medrxiv : the Preprint Server for Health Sciences|September 15, 2025
Enhancer-targeting CRISPR screens at coronary artery disease loci suggest shared mechanisms of disease riskMarkus Ramste, Chad Weldy, Soumya Kundu, et al.
Nature Cardiovascular Research|September 16, 2025
Smooth muscle expression of RNA editing enzyme ADAR1 controls activation of the RNA sensor MDA5 in atherosclerosisChad S Weldy, Qin Li, João P Monteiro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2022
HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and HumansYuanqing Ma, Allison Joyce, Olivia Brandenburg, et al.
The New England Journal of Medicine|January 24, 2014
PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphomaAjay K Gopal, Brad S Kahl, Sven de Vos, et al.
Blood|February 8, 2019
Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapyKevin A Hay, Jordan Gauthier, Alexandre V Hirayama, et al.
Blood|February 21, 2019
The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cellsAlexandre V Hirayama, Jordan Gauthier, Kevin A Hay, et al.
Pageof 19